Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Trial Profile

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Epacadostat (Primary) ; Maveropepimut-S (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DeCidE; DeCidE1; DeCidE1
  • Sponsors IMV
  • Most Recent Events

    • 12 Feb 2024 According to a BioVaxys media release, data from this study were presented at the 2023 SGO Annual Meeting on Women's Cancer .
    • 01 May 2023 Results (n=22; March 2019 to June 2021) assessing the safety and effectiveness of maveropepimut-S with cyclophosphamide in patients with recurrent ovarian cancer, published in the Clinical Cancer Research.
    • 19 Apr 2023 T cell repertoires of pre- and on-treatment (on-Tx) tumor biopsies of patients from this trial to further investigate the fate of T cells elicited by the MVP-S based therapy presented at the 114th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top